How much revenue does Anhui Fengyuan Pharmaceutical make?

Anhui Fengyuan Pharmaceutical reported 3.86 billion CNY in revenue for fiscal year 2025, down 10.0% from 4.28 billion CNY in fiscal year 2024. In Q1 2026 revenue was 835.92 million CNY.

What is Anhui Fengyuan Pharmaceutical's largest business segment?

Drug Retail Distribution, with 2.13 billion CNY or 52% of segment revenue in fiscal year 2024. Next: Pharmaceutical Manufacturing (48%).

What companies are similar to Anhui Fengyuan Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Beijing Centergate Technologies (holding) Co., Ltd. (000931.SZ), Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ), Shanghai Fudan Forward S&T Co., Ltd (600624.SS), Honz Pharmaceutical Co., Ltd. (300086.SZ).

Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) Stock

About Anhui Fengyuan Pharmaceutical Co., Ltd.

Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company offers biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine preparations, processed Chinese medicinal herbs, and raw materials. It also provides antipyretics and analgesics, gynecological and pediatric drugs, nervous system drugs, cardiovascular system drugs, u...

At a glance

Anhui Fengyuan Pharmaceutical reported revenue of 3.86 billion CNY for fiscal year 2025, down 10.0% from fiscal year 2024, and net income of 99.42 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 835.92 million CNY, down 11.1% from a year before. Its largest business segment, Drug Retail Distribution, brought in 52% of segment revenue in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.